Latest Breaking News On - Department of radiation oncology - Page 1 : comparemela.com

Postdoctoral Associate- Medical Image Analysis job with Baylor College of Medicine (BCM)

Postdoctoral Associate- Medical Image Analysis job in Houston, Texas (US) with Baylor College of Medicine (BCM). Apply Today.

Texas
United-states
Texas-medical-center
Houston
Baylor-college-of-medicine
America
Varian-varisource
Danl-duncan
Siemens
Baylor-st-luke-medical-center
Harris-health-smith-clinic
Collaborative-research

Adlai Nortye Ltd. to Present Encouraging Data of the

Adlai Nortye Ltd. to Present Encouraging Data of the
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New-jersey
United-states
Peking
Beijing
China
Singapore
Hangzhou
Zhejiang
Chicago
Illinois
American
Chinese

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-states
Chicago
Illinois
Hangzhou
Zhejiang
China
Singapore
Peking
Beijing
New-jersey
Chinese
American

AstraZeneca: India's drug regulator orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects |

DCGI orders withdrawal of AstraZeneca's Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was

India
Delhi
Abhishek-shankar
Department-of-radiation-oncology
Astrazeneca-pharma-india
Astrazeneca
Dr-br-ambedkar-institute-rotary-cancer-hospital
Drug-controller-general
Astrazeneca-pharma-india-limited
Olaparib-tablets
Assistant-professor
Radiation-oncology

Docs support drug regulator's move to withdraw Olaparib for some cancer patients

Oncologists on Thursday supported the Drug Controller General of India's (DCGI) mandate to state authorities to withdraw AstraZeneca's anticancer generic drug Olaparib over safety concerns.Olaparib is a chemotherapy drug and is used to treat .

India
Delhi
New-delhi
Shyam-aggarwal
Abhishek-shankar
Astrazeneca-olaparib
Rajeev-singh-raghuvanshi
Astrazeneca
Dr-br-ambedkar-institute-rotary-cancer-hospital
Department-of-radiation-oncology
Drug-controller-general
Astrazeneca-pharma-india